肉苁蓉多糖影响肠道菌群抑制Toll样受体4/核因子κB途径改善小鼠糖尿病肾病

摘要/Abstract

摘要： 摘要：本研究旨在探究肉苁蓉多糖（cistanche deserticola polysaccharides，CDPs）对糖尿病肾病（diabetic nephropathy，DN）小鼠模型的改善作用及其可能机制。通过高糖高脂饮食结合STZ注射建立DN模型，将36只C57BL/6N雄性小鼠随机分组，给予CDPs不同剂量处理，持续4周。检测小鼠的生理指标、肾功能、炎症因子和肠道菌群变化。结果显示，CDPs显著改善DN小鼠的一般状态和肾脏病理结构，降低血糖、尿蛋白等指标，减少炎症因子和纤维化因子的水平。此外，CDPs影响肠道菌群平衡，增加有益菌丰度，降低潜在致病菌，改善肠道屏障功能。CDPs还抑制TLR4/NF-κB信号通路的活化，减少LPS的释放。综上，CDPs通过影响肠道菌群和抑制炎症信号通路，对DN小鼠模型表现出改善作用，为DN治疗提供了新的思路。

关键词: 肉苁蓉多糖, 糖尿病肾病, 肠道屏障, 肠道菌群, Toll样受体4, 核因子κB

Abstract: Abstract: The objective of this study is to investigate the ameliorative effects and potential mechanisms of Cistanche deserticola polysaccharides (CDPs) on a diabetic nephropathy (DN) mouse model. The DN model was established by administering a high-sugar, high-fat diet combined with intraperitoneal injection of streptozotocin (STZ). Thirty-six C57BL/6N male mice were randomly divided into groups and treated with different doses of CDPs for 4 weeks. Physiological indices, renal function, inflammatory factors, and intestinal microbiota changes were assessed. The results showed that CDPs significantly improved the general condition and renal histopathological structure of DN mice, reduced blood glucose, urinary protein, and levels of inflammatory and fibrotic factors. Additionally, CDPs affected the balance of the intestinal microbiota, increased the abundance of beneficial bacteria, decreased potential pathogenic bacteria, and improved intestinal barrier function. CDPs also inhibited the activation of the TLR4/NF-κB signaling pathway and reduced the release of lipopolysaccharide (LPS). In conclusion, CDPs exhibit ameliorative effects on the DN mouse model by affecting the intestinal microbiota and inhibiting inflammatory signaling pathways, offering new insights for the treatment of DN.

Key words: Cistanche deserticola polysaccharide, diabetic nephropathy, intestinal barrier, intestinal flora, Toll like receptor 4, nuclear factor κB

罗欣杰杨建华胡君萍. 肉苁蓉多糖影响肠道菌群抑制Toll样受体4/核因子κB途径改善小鼠糖尿病肾病[J]. 食品科学, 0, (): 0-0.

Xinjie Luo Jun-Ping HU. Cistanche deserticola polysaccharides affect intestinal flora and inhibit TLR4 / NF-κB signaling pathway to improve diabetic nephropathy in mice[J]. FOOD SCIENCE, 0, (): 0-0.

参考文献

[1] UMANATH K, LEWIS J B. Update on Diabetic Nephropathy: Core Curriculum 2018[J]. Am J Kidney Dis, 2018,71(6): 884-895. [2] SHEU N W, HUANG S H, WU D C, et al. Effects of Helicobacter pylori treatment on the incidences of autoimmune diseases and inflammatory bowel disease in patients with diabetes mellitus[J]. PLoS One, 2022,17(5): e265323. [3] RYSZ J, FRANCZYK B, ?AWI?SKI J, et al. The Impact of CKD on Uremic Toxins and Gut Microbiota[J]. Toxins (Basel), 2021,13(4). [4] ZHU T, HU B Y, ZHANG Y Q, et al. The role of microbial metabolites in diabetic kidney disease[J]. Heliyon, 2023,9(7): e17844. [5] MOSTERD C M, KANBAY M, van den BORN B, et al. Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression[J]. Best Pract Res Clin Endocrinol Metab, 2021,35(3): 101484. [6] 王利, 松伟, 刘小雪, 等. 肉苁蓉生物活性成分及功效的研究进展[J]. 食品科技, 2023,48(02): 208-214. [7] 宋志宏雷丽屠鹏飞. 肉苁蓉属植物的药理活性研究进展[J]. 中草药, 2003(09): 113-115. [8] 屠鹏飞, 姜勇. 中药肉苁蓉的本草再考证[J]. 中国中药杂志, 2022,47(20): 5670-5679. [9] 荒漠肉苁蓉和管花肉苁蓉多糖的结构特征及其基于肿瘤相关巨噬细胞的抗肿瘤作用研究 {Author}:崔永生[D]. 天津医科大学, 2021. [10] 邓楠, 申雅娟, 丁辉, 等. 肉苁蓉多糖类成分药理作用研究进展[J]. 辽宁中医药大学学报, 2020,22(06): 67-71. [11] 许玮仪, 姜振邦, 范晶, 等. 离子色谱-积分脉冲安培法测定肉苁蓉多糖的单糖组成及游离单糖含量[J]. 药学学报, 2023,58(08): 2476-2482. [12] 徐万爱, 杨丹阳, 吴静雨, 等. 肉苁蓉的主要化学成分及生物活性研究进展[J]. 中华中医药学刊: 1-13. [13] FU Z, HAN L, ZHANG P, et al. Cistanche polysaccharides enhance echinacoside absorption in vivo and affect the gut microbiota[J]. Int J Biol Macromol, 2020,149: 732-740. [14] JINGNA G, YIZHOU Z, HONGMEI Y, et al. Cistanche deserticola polysaccharide regulated the gut microbiota-SCFAs-Th17/Treg cell axis and ameliorated the inflammation of postmenopausal osteoporosis[J]. Journal of Functional Foods, 2023,109. [15] YUAN G, BING L, HONG L, et al. Cistanche deserticola polysaccharides alleviate cognitive decline in aging model mice by restoring the gut microbiota-brain axis.[J]. Aging, 2021,13. [16] SONG D, CAO Z, LIU Z, et al. Cistanche deserticola polysaccharide attenuates osteoclastogenesis and bone resorption via inhibiting RANKL signaling and reactive oxygen species production[J]. J Cell Physiol, 2018,233(12): 9674-9684. [17] 朱金惠, 王玲, 陶金华, 等. 基于“肠-肾”轴理论的肠道微生态影响慢性肾病发生发展的机制及干预治疗[J]. 南京中医药大学学报, 2023,39(10): 1054-1062. [18] JANDHYALA S M, TALUKDAR R, SUBRAMANYAM C, et al. Role of the normal gut microbiota[J]. World J Gastroenterol, 2015,21(29): 8787-8803. [19] HO H J, KIKUCHI K, OIKAWA D, et al. SGLT-1-specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine-induced renal failure[J]. Physiol Rep, 2021,9(24): e15092. [20] PUSHPANATHAN P, MATHEW G S, SELVARAJAN S, et al. Gut microbiota and its mysteries[J]. Indian J Med Microbiol, 2019,37(2): 268-277. [21] LEE Y, LEE H Y. Revisiting the Bacterial Phylum Composition in Metabolic Diseases Focused on Host Energy Metabolism[J]. Diabetes Metab J, 2020,44(5): 658-667. [22] NIE K, MA K, LUO W, et al. Roseburia intestinalis: A Beneficial Gut Organism From the Discoveries in Genus and Species[J]. Front Cell Infect Microbiol, 2021,11: 757718. [23] LUO M, CAI J, LUO S, et al. Causal effects of gut microbiota on the risk of chronic kidney disease: a Mendelian randomization study[J]. Front Cell Infect Microbiol, 2023,13: 1142140. [24] ZHENG Z, LYU W, REN Y, et al. Allobaculum Involves in the Modulation of Intestinal ANGPTLT4 Expression in Mice Treated by High-Fat Diet[J]. Front Nutr, 2021,8: 690138. [25] HUACHONG X, SHIQI W, YAWEN J, et al. Poria cocos Polysaccharide Ameliorated Antibiotic-Associated Diarrhea in Mice via Regulating the Homeostasis of the Gut Microbiota and Intestinal Mucosal Barrier[J]. International Journal of Molecular Sciences, 2023,24(2): 1423. [26] TILG H, ZMORA N, ADOLPH T E, et al. The intestinal microbiota fuelling metabolic inflammation[J]. Nat Rev Immunol, 2020,20(1): 40-54. [27] 朱金惠, 王玲, 陶金华, 等. 基于“肠-肾”轴理论的肠道微生态影响慢性肾病发生发展的机制及干预治疗[J]. 南京中医药大学学报, 2023,39(10): 1054-1062. [28] 唐余燕, 孙蔚倩, 贺海东, 等. 肠黏膜TLR4/NF-κB通路激活与伪无菌IgA肾病小鼠肾损害有关[J]. 细胞与分子免疫学杂志, 2023,39(10): 865-871. [29] LIU M, ZEN K. Toll-Like Receptors Regulate the Development and Progression of Renal Diseases[J]. Kidney Dis (Basel), 2021,7(1): 14-23. [30] MUDALIAR H, POLLOCK C, PANCHAPAKESAN U. Role of Toll-like receptors in diabetic nephropathy[J]. Clin Sci (Lond), 2014,126(10): 685-694. [31] WANG Z, NI X, ZHANG L, et al. Toll-Like Receptor 4 and Inflammatory Micro-Environment of Pancreatic Islets in Type-2 Diabetes Mellitus: A Therapeutic Perspective[J]. Diabetes Metab Syndr Obes, 2020,13: 4261-4272. [32] WANG F, LIU C, REN L, et al. Sanziguben polysaccharides improve diabetic nephropathy in mice by regulating gut microbiota to inhibit the TLR4/NF-κB/NLRP3 signalling pathway[J]. Pharm Biol, 2023,61(1): 427-436. [33] WENG X, ZHAO B, FENG S, et al. Chemical composition and adjuvant properties of the macromolecules from cultivated Cistanche deserticola Y. C. Ma as an immunopotentiator[J]. Int J Biol Macromol, 2022,220: 638-658